Myriad Genetics, Inc. (MYGN) News
Filter MYGN News Items
MYGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MYGN News Highlights
- For MYGN, its 30 day story count is now at 6.
- Over the past 15 days, the trend for MYGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DEC are the most mentioned tickers in articles about MYGN.
Latest MYGN News From Around the Web
Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) AnticipationPiper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women’s health. It pioneered and was the market leader in BRCA testing for over ten y |
Myriad Genetics' (MYGN) New Platform to Advance Cancer CareMyriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results. |
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial GuidanceScott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective Ja |
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient CareThe Myriad Collaborative Research Registry has more than one million patient casesSALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest e |
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX WoesMyriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test. |
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Here's Why You Should Retain Myriad Genetics (MYGN) Stock NowInvestors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes. |
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant ParentsSALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby’s predicted |
Myriad Genetics (MYGN) Expands Pharma Services With New PactMyriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration. |
Myriad Genetics and Personalis Partner to Market Solutions to Pharma CustomersMyriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer testsSALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusive colla |